Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 12,232 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Plasma Cell Myeloma
Interventions: Best Practice, Kefir, Quality-of-Life Assessment, Questionnaire Administration; Other · Dietary Supplement
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Multiple Myeloma, Plasma Cell Disorder
Interventions: Tai Chi, Education; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Pomalidomide; Procedure · Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Migraine Headache, With or Without Aura
Interventions: Staccato Placebo, Staccato Prochlorperazine 5 mg, Staccato Prochlorperazine 10 mg; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Mount Vernon, New York

Conditions: Adult Caregivers of Individuals With TSC, Tuberous Sclerosis Complex (TSC)
Interventions: Well-Beans for Caregivers Program; Behavioral
Lead sponsor: Vrije Universiteit Brussel; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Multiple Sclerosis
Interventions: Natalizumab; Drug
Lead sponsor: Multiple Sclerosis Center of Northeastern New York; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Latham, New York

Conditions: Multiple Myeloma
Interventions: PHA-739358; Drug
Lead sponsor: Nerviano Medical Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Scottsdale, Arizona • Chicago, Illinois

Conditions: Multiple Sclerosis, RRMS, Relapsing Remitting MS
Interventions: HP 13C pyruvate injection, MRI Scanner; Drug · Device
Lead sponsor: Ari Green; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hyponatremia Symptomatic, Osmotic Demyelination Syndrome, Cerebral Edema
Interventions: Hypertonic 3% saline; Drug
Lead sponsor: Rochester General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cytomegalovirus Retinitis, HIV Infections, Gastrointestinal Diseases
Interventions: Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 17
States / cities: San Francisco, California • Denver, Colorado • Wilmington, Delaware + 12 more

Conditions: Spondylolisthesis
Interventions: Not listed
Lead sponsor: NuVasive; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 9
States / cities: Jacksonville, Florida • Kissimmee, Florida • Savannah, Georgia + 6 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: bortezomib, melphalan, pegylated liposomal doxorubicin hydrochloride; Drug
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Seasonal Allergic Rhinitis
Interventions: ACT-129968, Placebo, Cetirizine; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 12 Years to 76 Years
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more

Conditions: Schizophrenia
Interventions: SCA-136; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Glendale, California

Conditions: Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Interventions: Droxidopa, Placebo Oral Tablet; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, CDH
Interventions: Trinity CoC Total Hip System, Trinity Ceramic-on-Poly THR; Device
Lead sponsor: Corin; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 9
States / cities: Little Rock, Arkansas • Parker, Colorado • Hartford, Connecticut + 5 more

Conditions: Arthritis, Rheumatoid, Lung Diseases, Interstitial
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 2 more

Conditions: Multiple System Atrophy
Interventions: AAV2-GDNF gene therapy, Sham (Placebo) Surgery; Biological · Procedure
Lead sponsor: Brain Neurotherapy Bio, Inc.; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Irvine, California • Boca Raton, Florida • Boston, Massachusetts + 4 more

Conditions: ADHD, ADD
Interventions: Dexmethylphenidate HCl extended-release capsules; Drug
Lead sponsor: Novartis; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 252 participants
Timeline: 2006
U.S. locations: 25
States / cities: Mesa, Arizona • Little Rock, Arkansas • Los Angeles, California + 21 more

Conditions: Multiple Myeloma
Interventions: Bortezomib, Sorafenib; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Bethesda, Maryland • Nashville, Tennessee

Conditions: Facial Injuries, Mandible Fracture, Le Fort, Zygomaticomaxillary Complex Fracture, Nasal Fracture, Orbital Fractures, Zygoma Fracture, Orbital Floor Fracture, Facial Laceration
Interventions: IMPACT-G Module, IMPACT-N Module, IMPACT-O Module, IMPACT-J Module, 15D Control Survey; Other
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Sacramento, California • San Francisco, California • Memphis, Tennessee

Conditions: Fatigue, Dyspnea, Cognitive Impairment, Muscle Pain
Interventions: the multi-domain Tai Chi Digital therapy Software Application; Device
Lead sponsor: Tim Shi; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Ellicott City, Maryland

Conditions: GastroEsophageal Cancer, Gastric Cancer
Interventions: Lenvatinib, Pembrolizumab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 2
States / cities: New York, New York

Conditions: Kaposi Sarcoma
Interventions: liposomal doxorubicin, pomalidomide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Fermented Milk Supplementation on Symptoms of Disease and Treatment in Patients With Multiple Myeloma

Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

Staccato Prochlorperazine in Migraine (in Clinic)

TANDem-2: Closing the Gap to Interventions for TAND

Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab

PHA-739358 for the Treatment of Multiple Myeloma

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (ODS) and Rapid Correction of Hyponatremia

The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV

XLIF® vs. MAS®TLIF for the Treatment of Symptomatic Lumbar Degenerative Spondylolisthesis With or Without Central Stenosis.

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis

Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

Trinity™ BIOLOX Delta™ CoC THR Multi-center Study

Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors

GDNF Gene Therapy for Multiple System Atrophy

Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

Multi-Institutional IMPACT Validation

TaiChi-DTx for Treating Long Covid Symptoms

A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma